Sentence examples for between the two combination from inspiring English sources
46 BPO/clin was more efficacious than BPO monotherapy for reducing inflammatory lesions, and there was no difference in efficacy between the two combination therapies.
52 Finally, a recently published study of the combination of pioglitazone and sibutramine in type 2 diabetes patients intolerant to metformin and treated with sibutramine has shown a substantial equivalence in efficacy and tolerability between the two combination treatments.
As previously discussed, Leyden et al compared BPO/clin (5%/1%) vs BPO (5%) or BPO/erythro (5%/3%) in a 10-week study of 492 patients, showing no differences between the two combination therapies, however BPO/erythro was more efficacious than BPO alone.
Randomised clinical trials comparing the combination of paclitaxel with either cisplatin or with carboplatin in patients with advanced-stage OVCA found no significant differences in efficacy between the two combination treatments, although there was generally an improved tolerability for the carboplatin-containing regimen (Neijt et al, 2000; du Bois et al, 2003; Ozols et al, 2003).
Although the results from ((omega _{{mathrm{Frag}}}), (omega _{{mathrm{RT}}}), (omega _{{mathrm{Refs}}} in {0,1})) above indicated that the term (S_{C_{{mathrm{CRC + CERC + CDC}}}}) yielded the best result for ChemSpider with 411 top 1 ranks, (S_{C_{{mathrm{CRC}}}}) yielded 410 top 1 ranks for the same calculations, indicating that there is little difference between the two combinations.
A total of two adenoma patients overlapped between the two combinations.
However, the numbers of detected jiDE genes were different between the two combinations.
A major difference between the two combinations is that the latter is heterozygous for the skl locus.
The ranges of values were similar for the fixed and non-fixed combination, and changes went both ways between the two combinations: for DHA and DEAQ, values increased in 46 and 35% of patients, respectively, and decreased in 54 and 65%, respectively.
At the end of the study no differences were observed between the two combinations on metabolic improvement and reduction in Hcy levels, while reduction in Lp- a) was observed onLp- a the pioglitazone/metformin group (Derosa et al. 2006b).
The distributions of AUC values for two edgeR-related combinations (edgeR/TbT and edgeR/default) under three conditions (PA = 50, 70, and 90% with a fixed PDEG value of 20%) are shown in Figure 2. The performances between the two combinations were very similar when PA = 50%.
